MD&M 2026 Keynote: $6.1B Advice From Ray Cohen and Tom West!
Why It Matters
The discussion reshapes how medtech entrepreneurs and investors approach product development and fundraising, influencing which technologies will ultimately reach patients and drive industry growth.
Key Takeaways
- •Define innovation vs iteration in medtech, challenge assumptions.
- •VC focus on quick returns drives incremental product strategies.
- •Large strategics risk stifling innovation post‑acquisition of assets.
- •Successful exits need clear differentiation and strong advisory board.
- •AI and big‑tech entry reshape medtech funding for moonshots.
Summary
The MD&M West 2026 keynote, titled “Disrupting the Status Quo: Are We Innovating or Just Iterating?”, brought together veteran deal‑maker Ray Cohen and former J&J executive Tom West to debate what true innovation looks like in medical technology.
Cohen warned that venture capitalists are primarily chasing rapid returns, which pushes startups toward incremental improvements that fit a tidy exit narrative. West highlighted how large strategic buyers can provide scale but often mute the original disruptive spark of an asset unless new leadership actively champions continued innovation.
Cohen cited his $3.7 billion Axonics sale to Boston Scientific and a recent $1 billion sales milestone that treated 300,000 patients, underscoring the payoff of clear differentiation. West recounted the $1.1 billion Intersect ENT acquisition by Medtronic and the $650 million Nalo exit, illustrating both the upside and the risk of integration.
For medtech founders, the takeaway is clear: articulate a unique value proposition, build a strong advisory board, and secure capital that aligns with long‑term innovation goals. As AI and big‑tech firms move into healthcare, companies that can balance speed, scale, and moonshot ambition will attract the next wave of funding.
Comments
Want to join the conversation?
Loading comments...